BCYC
Price
$7.47
Change
+$0.30 (+4.18%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
519.4M
22 days until earnings call
CRNX
Price
$29.37
Change
+$0.31 (+1.07%)
Updated
Jul 8, 04:59 PM (EDT)
Capitalization
2.75B
30 days until earnings call
Interact to see
Advertisement

BCYC vs CRNX

Header iconBCYC vs CRNX Comparison
Open Charts BCYC vs CRNXBanner chart's image
Bicycle Therapeutics
Price$7.47
Change+$0.30 (+4.18%)
Volume$2.26K
Capitalization519.4M
Crinetics Pharmaceuticals
Price$29.37
Change+$0.31 (+1.07%)
Volume$16K
Capitalization2.75B
BCYC vs CRNX Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. CRNX commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and CRNX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (BCYC: $7.50 vs. CRNX: $29.37)
Brand notoriety: BCYC and CRNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 68% vs. CRNX: 72%
Market capitalization -- BCYC: $519.4M vs. CRNX: $2.75B
BCYC [@Biotechnology] is valued at $519.4M. CRNX’s [@Biotechnology] market capitalization is $2.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.39B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileCRNX’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • CRNX’s FA Score: 0 green, 5 red.
According to our system of comparison, BCYC is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while CRNX’s TA Score has 4 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • CRNX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, BCYC is a better buy in the short-term than CRNX.

Price Growth

BCYC (@Biotechnology) experienced а +6.69% price change this week, while CRNX (@Biotechnology) price change was +3.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 30, 2025.

CRNX is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.75B) has a higher market cap than BCYC($519M). CRNX YTD gains are higher at: -42.558 vs. BCYC (-46.429). BCYC has higher annual earnings (EBITDA): -200.61M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. BCYC (793M). BCYC has less debt than CRNX: BCYC (8.33M) vs CRNX (50.8M). BCYC has higher revenues than CRNX: BCYC (25.7M) vs CRNX (760K).
BCYCCRNXBCYC / CRNX
Capitalization519M2.75B19%
EBITDA-200.61M-373.49M54%
Gain YTD-46.429-42.558109%
P/E RatioN/AN/A-
Revenue25.7M760K3,382%
Total Cash793M1.27B62%
Total Debt8.33M50.8M16%
FUNDAMENTALS RATINGS
BCYC vs CRNX: Fundamental Ratings
BCYC
CRNX
OUTLOOK RATING
1..100
7453
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
91
Overvalued
PROFIT vs RISK RATING
1..100
10070
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
6564
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
30n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (20) in the null industry is significantly better than the same rating for CRNX (91) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew significantly faster than CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (70) in the Pharmaceuticals Major industry is in the same range as BCYC (100) in the null industry. This means that CRNX’s stock grew similarly to BCYC’s over the last 12 months.

CRNX's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as BCYC (96) in the null industry. This means that CRNX’s stock grew similarly to BCYC’s over the last 12 months.

CRNX's Price Growth Rating (64) in the Pharmaceuticals Major industry is in the same range as BCYC (65) in the null industry. This means that CRNX’s stock grew similarly to BCYC’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as BCYC (100) in the null industry. This means that CRNX’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCCRNX
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 7 days ago
82%
Bullish Trend 6 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 8 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USBLX28.33N/A
N/A
Victory Growth and Tax Strategy
FIGSX19.80N/A
N/A
Fidelity Series International Growth
CSRYX38.81N/A
N/A
Columbia Select Large Cap Value Inst3
STRLX59.60N/A
N/A
Sterling Capital MdCp Relatv Val A
FSCWX32.91N/A
N/A
Nuveen Small Cap Value R6

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+4.60%
XNCR - BCYC
54%
Loosely correlated
+4.16%
RPTX - BCYC
51%
Loosely correlated
+7.75%
RLAY - BCYC
50%
Loosely correlated
+1.13%
INO - BCYC
48%
Loosely correlated
+0.75%
RCUS - BCYC
45%
Loosely correlated
+3.41%
More

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.07%
XNCR - CRNX
59%
Loosely correlated
+4.16%
TRDA - CRNX
57%
Loosely correlated
+2.73%
IDYA - CRNX
55%
Loosely correlated
+1.37%
RVMD - CRNX
55%
Loosely correlated
-0.63%
DYN - CRNX
55%
Loosely correlated
+2.57%
More